# Extracted Content from https://ndc.services.cdc.gov/case-definitions/zika-virus-disease-and-zika-virus-infection-2016-06-01/

Zika Virus Disease and Zika Virus Infection 2016 Case Definition, Approved June 2016 | CDC  
Skip directly to site content  
Skip directly to search  
An official website of the United States government  
Here's how you know  
Official websites use .gov  
A .gov website belongs to an official government organization in the United States.  
Secure .gov websites use HTTPS  
A  
lock  
(  
) or  
https://  
means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.  
National Notifiable Diseases Surveillance System (NNDSS)  
Explore Topics  
Search  
Search  
Clear Input  
For Everyone  
About About National Notifiable Diseases Surveillance System  
What is Case Surveillance?  
Case Surveillance Modernization  
Infectious Disease Tables  
Non-Infectious Disease Data  
Technical Resource Center  
Case Surveillance in Action  
Contact Us  
View all  
Related Topics:  
NDC Application  
View All  
search  
close search  
search  
National Notifiable Diseases Surveillance System (NNDSS)  
Menu  
Close  
search  
For Everyone  
About About National Notifiable Diseases Surveillance System  
What is Case Surveillance?  
Case Surveillance Modernization  
Infectious Disease Tables  
Non-Infectious Disease Data  
Technical Resource Center  
Case Surveillance in Action  
Contact Us  
View All  
Related Topics  
NDC Application  
View All  
National Notifiable Diseases Surveillance System (NNDSS)  
About About National Notifiable Diseases Surveillance System  
What is Case Surveillance?  
Case Surveillance Modernization  
Infectious Disease Tables  
Non-Infectious Disease Data  
Technical Resource Center  
Case Surveillance in Action  
Contact Us  
View All  
April 16, 2021  
Case Definitions  
Message Mapping Guides  
Supporting Documents for Implementation  
Event Codes & Other Surveillance Resources  
Zika Virus Disease and Zika Virus Infection  
2016 Case Definition, Approved June 2016  
Zika Virus Disease and Zika Virus Infection  
Case Definition  
NOTE:  
A surveillance case definition is a set of uniform criteria used to define a disease for public health surveillance. Surveillance case definitions enable public health officials to classify and count cases consistently across reporting jurisdictions. Surveillance case definitions are not intended to be used by healthcare providers for making a clinical diagnosis or determining how to meet an individual patient’s health needs.  
CSTE Position Statement(s)  
16-ID-01  
Subtype(s)  
Zika virus disease, congenital  
Zika virus disease, non-congenital  
Zika virus infection, congenital  
Zika virus infection, non-congenital  
Background  
Zika virus (ZIKV), a flavivirus transmitted by  
Aedes  
species mosquitoes, was first identified in the Zika Forest by the Virus Research Institute in Uganda in a non-human primate in 1947 and from  
Aedes africanus  
mosquitoes in 1948. Before 2007, there had been only 14 human ZIKV disease cases documented. In 2007, an outbreak of ZIKV disease occurred on Yap Island, Federated States of Micronesia and the ensuing investigation included the first population-based epidemiological study of ZIKV infection and disease. It was estimated that 75% (attack rate) of the island’s inhabitants were infected with ZIKV resulting in 18% symptomatic and 82% asymptomatic infections. The most common symptoms documented in this outbreak were maculopapular rash, fever, arthralgia, and conjunctivitis. From 2013 to 2014 there was a large outbreak in French Polynesia where  
Aedes aegypti  
was considered the most important vector. There continues to be ongoing transmission in the Pacific Islands.  
Due to the rapidly evolving epidemic of Zika virus infection, the Council of State and Territorial Epidemiologists (CSTE) Executive Board developed an interim position statement to establish standardized case definitions for Zika virus disease and ZIKV congenital infection dated February 26, 2016, and to add these conditions to the Nationally Notifiable Diseases List. As laboratory testing for ZIKV has been more widely performed, limitations of the interpretation of serologic test results, including plaque reduction neutralization testing have been recognized, necessitating revisions to the laboratory criteria of the case definitions. Additionally, numerous asymptomatic persons, particularly pregnant women are tested for ZIKV infection and will meet laboratory criteria for infection. Because asymptomatic infection might be epidemiologically significant, revisions to the interim surveillance case definitions are proposed to include ZIKV infections without disease. Public health jurisdictions are encouraged to evaluate, report, and monitor identified ZIKV infections, particularly in pregnant women, that don’t meet the clinical criteria of the confirmed and probable congenital and non-congenital disease case classifications.  
Laboratory Criteria For Diagnosis  
Recent ZIKV infection  
Culture of ZIKV from blood, body fluid, or tissue;  
OR  
Detection of ZIKV antigen or viral ribonucleic acid (RNA) in serum, cerebrospinal fluid (CSF),placenta, umbilical cord, fetal tissue, or other specimen (e.g., amniotic fluid, urine, semen, saliva),  
OR  
Positive ZIKV immunoglobulin M (IgM) antibody test in serum or CSF  
with  
positive ZIKV neutralizing antibody titers and negative neutralizing antibody titers against dengue or other flaviviruses endemic to the region where exposure occurred  
Recent flavivirus infection, possible ZIKV  
Positive ZIKV IgM antibody test of serum or CSF with positive neutralizing antibody titers against ZIKV and dengue virus or other flaviviruses endemic to the region where exposure occurred  
Positive ZIKV IgM antibody test  
AND  
negative dengue virus IgM antibody test with no neutralizing antibody testing performed  
Epidemiologic Linkage  
Resides in or recent travel to an area with known ZIKV transmission; OR  
Sexual contact with a confirmed or probable case within the infection transmission risk window of ZIKV infection or person with recent travel to an area with known ZIKV transmission; OR  
Receipt of blood or blood products within 30 days of symptom onset; OR  
Organ or tissue transplant recipient within 30 days of symptom onset; OR  
Association in time and place with a confirmed or probable case; OR  
Likely vector exposure in an area with suitable seasonal and ecological conditions for potential local vectorborne transmission  
Subtype(s) Case Definition  
Expand All  
Zika virus disease, congenital  
Clinical Criteria  
Liveborn infant with congenital microcephaly, or intracranial calcifications, or structural brain or eye abnormalities, or other congenital central nervous system-related abnormalities not explained by another etiology.  
(As part of the complete evaluation of congenital microcephaly or other central nervous system [CNS] birth defects, testing for other congenital infections such as syphilis, toxoplasmosis, rubella, cytomegalovirus infection, lymphocytic choriomeningitis virus infection, and herpes simplex virus infections should be considered. An assessment of potential genetic and other teratogenic causes of the congenital anomalies should also be performed.)  
Case Classification  
Probable  
A neonate meets clinical criteria for congenital disease;  
AND  
The neonate’s mother has an epidemiologic linkage or meets laboratory criteria for recent ZIKV or flavivirus infection;  
AND  
The neonate has laboratory evidence of ZIKV or flavivirus infection by:  
Positive ZIKV IgM antibody test of serum or CSF collected within 2 days of birth;  
AND  
positive neutralizing antibody titers against ZIKV and dengue or other flaviviruses endemic to the region where exposure occurred;  
OR  
negative dengue virus IgM antibody test and no neutralizing antibody testing performed.  
Confirmed  
A neonate meets the clinical criteria for congenital disease  
AND  
meets one of the following laboratory criteria:  
ZIKV detection by culture, viral antigen, or viral RNA in fetal tissue, umbilical cord blood, or amniotic fluid; or neonatal serum, CSF, or urine collected within 2 days of birth;  
OR  
Positive ZIKV IgM antibody test of umbilical cord blood, neonatal serum or CSF collected within 2 days of birth  
with  
positive ZIKV neutralizing antibody titers and negative neutralizing antibody titers against dengue or other flaviviruses endemic to the region where exposure occurred.  
Zika virus disease, non-congenital  
Clinical Criteria  
A person with one or more of the following not explained by another etiology:  
Clinically compatible illness that includes  
acute onset of fever (measured or reported),  
OR  
maculopapular rash,  
OR  
arthralgia,  
OR  
conjunctivitis  
Complication of pregnancy  
fetal loss;  
OR  
fetus or neonate with congenital microcephaly, congenital intracranial calcifications, other structural brain or eye abnormalities, or other congenital central nervous system-related abnormalities including defects such as clubfoot or multiple joint contractures  
Guillain-Barré syndrome or other neurologic manifestations  
Case Classification  
Probable  
Meets clinical criteria for non-congenital disease;  
AND  
Has an epidemiologic linkage;  
AND  
Has laboratory evidence of recent ZIKV or flavivirus infection by:  
Positive ZIKV IgM antibody test of serum or CSF with:  
positive neutralizing antibody titers against ZIKV and dengue or other flaviviruses endemic to the region where exposure occurred;  
OR  
negative dengue virus IgM antibody test and no neutralizing antibody testing performed.  
Confirmed  
Meets clinical criteria for non-congenital disease;  
AND  
Has laboratory evidence of recent ZIKV infection by:  
Detection of ZIKV by culture, viral antigen or viral RNA in serum, CSF, tissue, or other specimen (e.g. amniotic fluid, urine, semen, saliva);  
OR  
Positive ZIKV IgM antibody test of serum or CSF  
with  
positive ZIKV neutralizing antibody titers and negative neutralizing antibody titers against dengue or other flaviviruses endemic to the region where exposure occurred.  
Zika virus infection, congenital  
Case Classification  
Probable  
A neonate who does not meet clinical criteria for a congenital disease case;  
BUT  
The neonate’s mother has an epidemiologic linkage or meets laboratory criteria for recent ZIKV or flavivirus infection;  
AND  
The neonate has laboratory evidence of ZIKV or flavivirus infection by:  
Positive ZIKV IgM antibody test of serum or CSF collected within 2 days of birth;  
AND  
negative dengue IgM antibody test and no neutralizing antibody testing performed;  
OR  
positive neutralizing antibody titers against ZIKV and dengue or other flaviviruses endemic to the region where exposure occurred.  
Confirmed  
A neonate who does not meet clinical criteria for a congenital disease case;  
BUT  
The neonate has laboratory evidence of recent ZIKV or flavivirus infection by:  
ZIKV detection by culture, viral antigen or viral RNA in fetal tissue, umbilical cord blood, or amniotic fluid; or neonatal serum, CSF, or urine collected within 2 days of birth;  
OR  
Positive ZIKV IgM antibody test of umbilical cord blood, neonatal serum or CSF collected within 2 days of birth  
with  
positive ZIKV neutralizing antibody titers and negative neutralizing antibody titers against dengue or other flaviviruses endemic to the region where exposure occurred.  
Zika virus infection, non-congenital  
Case Classification  
Probable  
A person who does not meet clinical criteria for non-congenital disease;  
BUT  
Has an epidemiologic linkage;  
AND  
Has laboratory evidence of recent ZIKV infection by:  
Positive ZIKV IgM antibody test of serum or CSF with:  
positive neutralizing antibody titers against ZIKV and dengue or other flaviviruses endemic to the region where exposure occurred;  
OR  
negative dengue IgM antibody test and no neutralizing antibody testing performed.  
Confirmed  
A person who does not meet clinical criteria for non-congenital disease;  
AND  
Has laboratory evidence of recent ZIKV infection by:  
Detection of ZIKV by culture, viral antigen or viral RNA in serum, CSF, tissue, or other specimen (e.g. amniotic fluid, urine, semen, saliva);  
OR  
Positive ZIKV IgM antibody test of serum or CSF  
with  
positive ZIKV neutralizing antibody titers and negative neutralizing antibody titers against dengue or other flaviviruses endemic to the region where exposure occurred.  
Comments  
CSTE approved position statement 16-ID-01 in June 2016, which modified the previous February 2016 interim case definition and naming convention from "Zika virus, congenital infection" to "Zika virus disease, congenital" and from "Zika virus disease, non-congenital infection" to "Zika virus disease, non-congenital".  
Related Case Definition(s)  
Zika Virus Disease | 2024 Case Definition  
Zika Virus Disease, Non-congenital Infection and Zika Virus, Congenital Infection | 2016 Interim Case Definition, Approved February 26, 2016  
Back to Top  
Sources  
Print  
Share  
Facebook  
LinkedIn  
Twitter  
Syndicate  
Content Source:  
Case Definitions  
Message Mapping Guides  
Supporting Documents for Implementation  
Event Codes & Other Surveillance Resources  
National Notifiable Diseases Surveillance System (NNDSS)  
NNDSS receives and shares case data from state, local, and territorial health departments to help public health monitor, control, and prevent serious diseases.  
View All  
About About National Notifiable Diseases Surveillance System  
What is Case Surveillance?  
Case Surveillance Modernization  
Infectious Disease Tables  
Non-Infectious Disease Data  
Technical Resource Center  
Case Surveillance in Action  
Contact Us  
View All  
Sign up for Email Updates  
Contact CDC  
Organization  
Policies  
Web Policies  
Languages  
Languages  
Español  
Language Assistance  
Archive  
CDC Archive  
Public Health Publications  
Contact Us  
About CDC  
Organization  
Policies  
Web Policies  
Languages  
Languages  
Español  
Language Assistance  
Archive  
CDC Archive  
Public Health Publications  
HHS.gov  
USA.gov